IL1B and malaria: In the co-dominant model, the risk of clinical malaria was only reduced among homozygote AA carriers of IL-1β rs1143634 SNP (AA vs GG, AOR = 0.14, 95%CI 0.03–0.75, P = 0.022), while both AA mutant homozygote and GA heterozygote individuals for FcγRIIA/CD32 rs1801274 SNP were significantly protected (AA vs GG, AOR = 0.48, 95%CI 0.26–0.87, P = 0.017 and GA vs GG, AOR = 0.61, 95%CI 0.42–0.89, P = 0.010) (Additional file 2: Table S2).